{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:33:06Z","timestamp":1790548386177,"version":"4.1.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s12640-019-9998-3","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T18:04:50Z","timestamp":1552673090000},"page":"635-653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats"],"prefix":"10.1007","volume":"35","author":[{"given":"Ghada A.","family":"Badawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai A.","family":"Abd El Fattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala F.","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moushira I.","family":"El Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"9998_CR1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/jnc.13087","volume":"133","author":"RM Abdelsalam","year":"2015","unstructured":"Abdelsalam RM, Safar MM (2015) Neuroprotective effects of vildagliptin in rat rotenone Parkinson\u2019s disease model: role of RAGE-NFkappaB and Nrf2-antioxidant signaling pathways. J Neurochem 133:700\u2013707","journal-title":"J Neurochem"},{"key":"9998_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.neures.2011.08.008","volume":"71","author":"AA Abdin","year":"2011","unstructured":"Abdin AA, Sarhan NI (2011) Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of alpha-lipoic acid against rotenone-induced Parkinsonism and L-dopa toxicity. Neurosci Res 71:387\u2013395","journal-title":"Neurosci Res"},{"key":"9998_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.2042-7158.2011.01394.x","volume":"64","author":"A Abuirmeileh","year":"2012","unstructured":"Abuirmeileh A, Harkavyi A, Rampersaud N, Lever R, Tadross JA, Bloom SR, Whitton PS (2012) Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat. J Pharm Pharmacol 64:637\u2013643","journal-title":"J Pharm Pharmacol"},{"key":"9998_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0166-4328(02)00180-8","volume":"136","author":"M Alam","year":"2002","unstructured":"Alam M, Schmidt WJ (2002) Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 136:317\u2013324","journal-title":"Behav Brain Res"},{"key":"9998_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbr.2003.08.014","volume":"151","author":"M Alam","year":"2004","unstructured":"Alam M, Mayerhofer A, Schmidt WJ (2004) The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA. Behav Brain Res 151:117\u2013124","journal-title":"Behav Brain Res"},{"issue":"Suppl 5","key":"9998_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00415-008-5004-3","volume":"255","author":"G Alves","year":"2008","unstructured":"Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP (2008) Epidemiology of Parkinson\u2019s disease. J Neurol 255(Suppl 5):18\u201332","journal-title":"J Neurol"},{"key":"9998_CR7","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","volume":"21","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov Today 21:802\u2013818","journal-title":"Drug Discov Today"},{"key":"9998_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10787-017-0331-6","volume":"25","author":"GA Badawi","year":"2017","unstructured":"Badawi GA, Abd El Fattah MA, Zaki HF, El Sayed MI (2017) Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson\u2019s disease. Inflammopharmacology 25:369\u2013382","journal-title":"Inflammopharmacology"},{"key":"9998_CR9","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131\u20132157","journal-title":"Gastroenterology"},{"key":"9998_CR10","first-page":"257","volume-title":"Theory and practice of histological techniques","author":"JD Banchroft","year":"1996","unstructured":"Banchroft JD, Stevens A, Turner DR (1996) Theory and practice of histological techniques, 4th edn. Churchill Livingstone, London, pp 257\u2013262","edition":"4"},{"key":"9998_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jnr.21483","volume":"86","author":"G Bertilsson","year":"2008","unstructured":"Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, Kortesmaa J, Mercer A, Nielsen E, Ronnholm H, Wikstrom L (2008) Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson\u2019s disease. J Neurosci Res 86:326\u2013338","journal-title":"J Neurosci Res"},{"key":"9998_CR12","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/81834","volume":"3","author":"R Betarbet","year":"2000","unstructured":"Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson\u2019s disease. Nat Neurosci 3:1301\u20131306","journal-title":"Nat Neurosci"},{"key":"9998_CR13","doi-asserted-by":"crossref","unstructured":"Betarbet R, Sherer TB and Greenamyre JT (2002) Animal models of Parkinson's disease. BioEssays 24:308\u2013318","DOI":"10.1002\/bies.10067"},{"key":"9998_CR14","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/j.1471-4159.2011.07376.x","volume":"118","author":"S Bido","year":"2011","unstructured":"Bido S, Marti M, Morari M (2011) Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J Neurochem 118:1043\u20131055","journal-title":"J Neurochem"},{"key":"9998_CR15","doi-asserted-by":"publisher","first-page":"15597","DOI":"10.1074\/jbc.M610893200","volume":"282","author":"M Bisaglia","year":"2007","unstructured":"Bisaglia M, Mammi S, Bubacco L (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 282:15597\u201315605","journal-title":"J Biol Chem"},{"key":"9998_CR16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.bbrc.2010.03.044","volume":"394","author":"M Bisaglia","year":"2010","unstructured":"Bisaglia M, Tosatto L, Munari F, Tessari I, de Laureto PP, Mammi S, Bubacco L (2010) Dopamine quinones interact with alpha-synuclein to form unstructured adducts. Biochem Biophys Res Commun 394:424\u2013428","journal-title":"Biochem Biophys Res Commun"},{"key":"9998_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/00002826-199010000-00006","volume":"13","author":"S Boyce","year":"1990","unstructured":"Boyce S, Rupniak NM, Steventon MJ, Iversen SD (1990) Nigrostriatal damage is required for induction of dyskinesia by L-DOPA in squirrel monkeys. Clin Neuropharmacol 13:448\u2013458","journal-title":"Clin Neuropharmacol"},{"key":"9998_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.nbd.2009.01.016","volume":"34","author":"JR Cannon","year":"2009","unstructured":"Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT (2009) A highly reproducible rotenone model of Parkinson\u2019s disease. Neurobiol Dis 34:279\u2013290","journal-title":"Neurobiol Dis"},{"key":"9998_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s007020200064","volume":"109","author":"A Carlsson","year":"2002","unstructured":"Carlsson A (2002) Treatment of Parkinson\u2019s with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm 109:777\u2013787","journal-title":"J Neural Transm"},{"key":"9998_CR20","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease. JAMA 311:1670\u20131683","journal-title":"JAMA"},{"key":"9998_CR21","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","volume":"4","author":"SC Cork","year":"2015","unstructured":"Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S (2015) Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab 4:718\u2013731","journal-title":"Mol Metab"},{"key":"9998_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","volume":"62","author":"DT Dexter","year":"2013","unstructured":"Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132\u2013144","journal-title":"Free Radic Biol Med"},{"key":"9998_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3","volume":"15","author":"DA Monte Di","year":"2000","unstructured":"Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ (2000) Relationship among nigrostriatal denervation, parkinsonism, and dyskinesia in the MPTP primate model. Mov Disord 15:459\u2013466","journal-title":"Mov Disord"},{"key":"9998_CR24","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2165\/00019053-200119100-00004","volume":"19","author":"RC Dodel","year":"2001","unstructured":"Dodel RC, Berger K, Oertel WH (2001) Health-related quality of life and healthcareutilisation in patients with Parkinson\u2019s disease: impact of motor fluctuations and dyskinesias. PharmacoEconomics 19:1013\u20131038","journal-title":"PharmacoEconomics"},{"key":"9998_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.nbd.2016.06.013","volume":"94","author":"M Dos-Santos-Pereira","year":"2016","unstructured":"Dos-Santos-Pereira M, da-Silva CA, Guimaraes FS, Del-Bel E (2016) Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action. Neurobiol Dis 94:179\u2013195","journal-title":"Neurobiol Dis"},{"key":"9998_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1006\/exnr.1996.6379","volume":"144","author":"JD Elsworth","year":"1997","unstructured":"Elsworth JD, Roth RH (1997) Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson\u2019s disease. Exp Neurol 144:4\u20139","journal-title":"Exp Neurol"},{"key":"9998_CR27","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/mds.21475","volume":"22","author":"G Fabbrini","year":"2007","unstructured":"Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (2007) Levodopa-induced dyskinesia. Mov Disord 22:1379\u20131389","journal-title":"Mov Disord"},{"key":"9998_CR28","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/1531-8249(200001)47:1<2::AID-ANA2>3.0.CO;2-B","volume":"47","author":"S Fahn","year":"2000","unstructured":"Fahn S (2000) The spectrum of levodopa-induced dyskinesia. Ann Neurol 47:S2\u2013S9 discussion S9\u201311","journal-title":"Ann Neurol"},{"key":"9998_CR29","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1523\/JNEUROSCI.22-03-00782.2002","volume":"22","author":"HM Gao","year":"2002","unstructured":"Gao HM, Hong JS, Zhang W, Liu B (2002) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22:782\u2013790","journal-title":"J Neurosci"},{"key":"9998_CR30","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1212\/WNL.38.9.1402","volume":"38","author":"WR Gibb","year":"1988","unstructured":"Gibb WR, Lees AJ (1988) A comparisons of clinical and pathological features of young and old-onset Parkinson\u2019s disease. Neurology 38:1402\u20131406","journal-title":"Neurology"},{"key":"9998_CR31","doi-asserted-by":"crossref","unstructured":"Guridi J, Gonzalez-Redondo R, Obeso JA (2012) Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson\u2019s disease. Parkinsons Dis 2012:943159","DOI":"10.1155\/2012\/943159"},{"key":"9998_CR32","doi-asserted-by":"publisher","first-page":"372","DOI":"10.4103\/1673-5374.202928","volume":"12","author":"RL Haining","year":"2017","unstructured":"Haining RL, Achat-Mendes C (2017) Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator. Neural Regen Res 12:372\u2013375","journal-title":"Neural Regen Res"},{"key":"9998_CR33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/jnr.22565","volume":"89","author":"A Hamilton","year":"2011","unstructured":"Hamilton A, Patterson S, Porter D, Gault VA, Holscher C (2011) Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res 89:481\u2013489","journal-title":"J Neurosci Res"},{"key":"9998_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1476-5381.2009.00486.x","volume":"159","author":"A Harkavyi","year":"2010","unstructured":"Harkavyi A, Whitton PS (2010) Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 159:495\u2013501","journal-title":"Br J Pharmacol"},{"key":"9998_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1742-2094-5-19","volume":"5","author":"A Harkavyi","year":"2008","unstructured":"Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson\u2019s disease. J Neuroinflammation 5:19","journal-title":"J Neuroinflammation"},{"key":"9998_CR36","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1002\/ana.410440717","volume":"4","author":"EC Hirsch","year":"1998","unstructured":"Hirsch EC, Hunot S, Damier P, Faucheux B (1998) Glial cells inflammation in Parkinson\u2019s disease: a role in neurodegeneration? Ann Neurol 4:S115\u2013S120","journal-title":"Ann Neurol"},{"key":"9998_CR37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2202-13-33","volume":"13","author":"K Hunter","year":"2012","unstructured":"Hunter K, Holscher C (2012) Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 13:33","journal-title":"BMC Neurosci"},{"key":"9998_CR38","unstructured":"ILAR (1996) Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington"},{"key":"9998_CR39","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1212\/WNL.61.6_suppl_3.S4","volume":"61","author":"P Jenner","year":"2003","unstructured":"Jenner P (2003) The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 61:S4\u2013S11","journal-title":"Neurology"},{"key":"9998_CR40","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrn2471","volume":"9","author":"P Jenner","year":"2008","unstructured":"Jenner P (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9:665\u2013677","journal-title":"Nat Rev Neurosci"},{"key":"9998_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.physbeh.2018.01.028","volume":"188","author":"AM Kabel","year":"2018","unstructured":"Kabel AM, Omar MS, Alhadhrami A, Alharthi SS, Alrobaian MM (2018) Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical immunohistochemical changes in experimentally-induced parkinsonism: role of toll-like receptor 4, TGF-beta1, NF-kappaB glucagon-like peptide 1. Physiol Behav 188:108\u2013118","journal-title":"Physiol Behav"},{"key":"9998_CR42","first-page":"4078","volume":"55","author":"EA Kandil","year":"2018","unstructured":"Kandil EA, Sayed RH, Ahmed LA, Abd El Fattah MA, El-Sayeh BM (2018) Modulatory role of Nurr1 activation and thrombin inhibition in the neuroprotective effects of dabigatran etexilate in rotenone-induced Parkinson\u2019s disease in rats. Mol Neurobiol 55:4078\u20134089","journal-title":"Mol Neurobiol"},{"key":"9998_CR43","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/1742-2094-9-276","volume":"9","author":"C Kappe","year":"2012","unstructured":"Kappe C, Tracy LM, Patrone C, Iverfeldt K, Sjoholm A (2012) GLP-1 secretion by microglial cells and decreased CNS expression in obesity. J Neuroinflammation 9:276","journal-title":"J Neuroinflammation"},{"key":"9998_CR44","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1677\/JOE-09-0132","volume":"202","author":"S Kim","year":"2009","unstructured":"Kim S, Moon M, Park S (2009) Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson\u2019s disease. J Endocrinol 202:431\u2013439","journal-title":"J Endocrinol"},{"key":"9998_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1353-8020(99)00022-X","volume":"5","author":"C Knott","year":"1999","unstructured":"Knott C, Wilkin GP, Stern G (1999) Astrocytes and microglia in the substantia nigra and caudate-putamen in Parkinson\u2019s disease. Parkinsonism Relat Disord 5:115\u2013122","journal-title":"Parkinsonism Relat Disord"},{"key":"9998_CR46","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/mds.20360","volume":"20","author":"N Kumar","year":"2005","unstructured":"Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE (2005) Levodopa-dyskinesia incidence by age of Parkinson\u2019s disease onset. Mov Disord 20:342\u2013344","journal-title":"Mov Disord"},{"key":"9998_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bbr.2010.04.034","volume":"213","author":"EL Lane","year":"2010","unstructured":"Lane EL, Dunnett SB (2010) Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat. Behav Brain Res 213:66\u201372","journal-title":"Behav Brain Res"},{"key":"9998_CR48","doi-asserted-by":"publisher","first-page":"e00421","DOI":"10.1042\/BSR20160437","volume":"36","author":"M Larsson","year":"2016","unstructured":"Larsson M, Lietzau G, Nathanson D, Ostenson CG, Mallard C, Johansson ME, Nystrom T, Patrone C, Darsalia V (2016) Diabetes negatively affects cortical and striatal GABAergic neurons: an effect that is partially counteracted by exendin-4. Biosci Rep 36:e00421","journal-title":"Biosci Rep"},{"key":"9998_CR49","first-page":"3094642","volume":"2016","author":"YS Lee","year":"2016","unstructured":"Lee YS, Jun HS (2016) Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediat Inflamm 2016:3094642","journal-title":"Mediat Inflamm"},{"key":"9998_CR50","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/brain\/123.7.1365","volume":"123","author":"CS Lee","year":"2000","unstructured":"Lee CS, Cenci MA, Schulzer M, Bjorklund A (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson\u2019s disease. Brain 123:1365\u20131379","journal-title":"Brain"},{"key":"9998_CR51","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/jnr.22596","volume":"89","author":"CH Lee","year":"2011","unstructured":"Lee CH, Yan B, Yoo KY, Choi JH, Kwon SH, Her S, Sohn Y, Hwang IK, Cho JH, Kim YM, Won MH (2011) Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J Neurosci Res 89:1103\u20131113","journal-title":"J Neurosci Res"},{"key":"9998_CR52","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.29.9_Part_1.1253","volume":"29","author":"RP Lesser","year":"1979","unstructured":"Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE (1979) Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29:1253\u20131260","journal-title":"Neurology"},{"key":"9998_CR53","doi-asserted-by":"publisher","first-page":"155S","DOI":"10.1592\/phco.27.12part2.155S","volume":"27","author":"M Lew","year":"2007","unstructured":"Lew M (2007) Overview of Parkinson\u2019s disease. Pharmacotherapy 27:155S\u2013160S","journal-title":"Pharmacotherapy"},{"key":"9998_CR54","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","volume":"303","author":"W Liu","year":"2015","unstructured":"Liu W, Jalewa J, Sharma M, Li G, Li L, Holscher C (2015) Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease. Neuroscience 303:42\u201350","journal-title":"Neuroscience"},{"key":"9998_CR55","doi-asserted-by":"publisher","first-page":"9977","DOI":"10.1073\/pnas.1402134111","volume":"111","author":"KM Lohr","year":"2014","unstructured":"Lohr KM, Bernstein AI, Stout KA, Dunn AR, Lazo CR, Alter SP, Wang M, Li Y, Fan X, Hess EJ, Yi H, Vecchio LM, Goldstein DS, Guillot TS, Salahpour A, Miller GW (2014) Increased vesicular monoamine transporter enhances dopamine release opposes Parkinson disease-related neurodegeneration in vivo. Proc Natl Acad Sci U S A 111:9977\u20139982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9998_CR56","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.nbd.2004.01.007","volume":"16","author":"M Lundblad","year":"2004","unstructured":"Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16:110\u2013123","journal-title":"Neurobiol Dis"},{"key":"9998_CR57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","volume":"194","author":"M Lundblad","year":"2005","unstructured":"Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G, Cenci MA (2005) Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 194:66\u201375","journal-title":"Exp Neurol"},{"key":"9998_CR58","unstructured":"Mahmoud GA, El-Azab MF, Desoky AA, El-Sayed NM, Moustafa YM (2014) Activation of GLP-1R preserves dopaminergic neurons in rotenone-induced parkinsonism. In. 6th International Conference on Natural Toxins 27-B6. Avilable from: \n                    https:\/\/www.egynattox.com\n                    \n                  . Accessed 15-16 Dec 2014"},{"key":"9998_CR59","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1006\/exnr.1998.7008","volume":"156","author":"GW Miller","year":"1999","unstructured":"Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, Levey AI (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson\u2019s disease. Exp Neurol 156:138\u2013148","journal-title":"Exp Neurol"},{"key":"9998_CR60","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuropharm.2014.10.007","volume":"89","author":"NN Nassar","year":"2015","unstructured":"Nassar NN, Al-Shorbagy MY, Arab HH, Abdallah DM (2015) Saxagliptin: a novel antiparkinsonian approach. Neuropharmacology 89:308\u2013317","journal-title":"Neuropharmacology"},{"key":"9998_CR61","first-page":"S13","volume":"55","author":"JA Obeso","year":"2000","unstructured":"Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW (2000) The evolution and origin of motor complications in Parkinson\u2019s disease. Neurology 55:S13\u2013S20 discussion S21\u201313","journal-title":"Neurology"},{"key":"9998_CR62","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/mds.20243","volume":"19","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F (2004) Levodopa in the treatment of Parkinson\u2019s disease: current controversies. Mov Disord 19:997\u20131005","journal-title":"Mov Disord"},{"key":"9998_CR63","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s007020050063","volume":"105","author":"J Opacka-Juffry","year":"1998","unstructured":"Opacka-Juffry J, Ashworth S, Ahier RG, Hume SP (1998) Modulatory effects of L-DOPA on D2 dopamine receptors in rat striatum measured using in vivo microdialysis and PET. J Neural Transm 105:349\u2013364","journal-title":"J Neural Transm"},{"key":"9998_CR64","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1185\/03007990902779319","volume":"25","author":"R Pahwa","year":"2009","unstructured":"Pahwa R, Lyons KE (2009) Levodopa-related wearing-off in Parkinson\u2019s disease: identification and management. Curr Med Res Opin 25:841\u2013849","journal-title":"Curr Med Res Opin"},{"key":"9998_CR65","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00001756-200403010-00035","volume":"15","author":"V Paille","year":"2004","unstructured":"Paille V, Brachet P, Damier P (2004) Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson\u2019s disease. Neuroreport 15:561\u2013564","journal-title":"Neuroreport"},{"key":"9998_CR66","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1074\/jbc.M508307200","volume":"281","author":"S Park","year":"2006","unstructured":"Park S, Dong X, Fisher TL, Dunn S, Omer AK, Weir G, White MF (2006) Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem 281:1159\u20131168","journal-title":"J Biol Chem"},{"key":"9998_CR67","doi-asserted-by":"publisher","first-page":"e58784","DOI":"10.1371\/journal.pone.0058784","volume":"8","author":"V Parthsarathy","year":"2013","unstructured":"Parthsarathy V, Holscher C (2013) Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PLoS One 8:e58784","journal-title":"PLoS One"},{"key":"9998_CR68","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2174\/1567205054367892","volume":"2","author":"T Perry","year":"2005","unstructured":"Perry T, Greig NH (2005) Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer\u2019s disease. Curr Alzheimer Res 2:377\u2013385","journal-title":"Curr Alzheimer Res"},{"key":"9998_CR69","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/mds.870020201","volume":"2","author":"N Quinn","year":"1987","unstructured":"Quinn N, Critchley P, Marsden CD (1987) Young onset Parkinson\u2019s disease. Mov Disord 2:73\u201391","journal-title":"Mov Disord"},{"key":"9998_CR70","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/mds.870120503","volume":"12","author":"AH Rajput","year":"1997","unstructured":"Rajput AH, Fenton M, Birdi S, Macaulay R (1997) Is levodopa toxic to human substantia nigra? Mov Disord 12:634\u2013638","journal-title":"Mov Disord"},{"issue":"Suppl 3","key":"9998_CR71","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ana.10513","volume":"53","author":"O Rascol","year":"2003","unstructured":"Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL (2003) Limitations of current Parkinson\u2019s disease therapy. Ann Neurol 53(Suppl 3):S3\u2013S12 discussion S12\u201315","journal-title":"Ann Neurol"},{"key":"9998_CR72","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/sj.bjp.0702474","volume":"126","author":"E Rivas","year":"1999","unstructured":"Rivas E, de Ceballos ML, Nieto O, Fontenla JA (1999) In vivo effects of new inhibitors of catechol-O-methyl transferase. Br J Pharmacol 126:1667\u20131673","journal-title":"Br J Pharmacol"},{"key":"9998_CR73","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0091-3057(89)90372-9","volume":"34","author":"JS Schneider","year":"1989","unstructured":"Schneider JS (1989) Levodopa-induced dyskinesia in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 34:193\u2013196","journal-title":"Pharmacol Biochem Behav"},{"key":"9998_CR74","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.parkreldis.2006.07.002","volume":"12","author":"JC Sharma","year":"2006","unstructured":"Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross I (2006) Cascade of levodopa dose and weight-related dyskinesia in Parkinson\u2019s disease (LD-WD-PD cascade). Parkinsonism Relat Disord 12:499\u2013505","journal-title":"Parkinsonism Relat Disord"},{"key":"9998_CR75","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11011-014-9627-z","volume":"30","author":"AN Sharma","year":"2015","unstructured":"Sharma AN, Pise A, Sharma JN, Shukla P (2015) Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats. Metab Brain Dis 30:719\u2013730","journal-title":"Metab Brain Dis"},{"key":"9998_CR76","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF03033289","volume":"1","author":"D Sulzer","year":"2000","unstructured":"Sulzer D, Zecca L (2000) Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res 1:181\u2013195","journal-title":"Neurotox Res"},{"key":"9998_CR77","doi-asserted-by":"publisher","first-page":"11869","DOI":"10.1073\/pnas.97.22.11869","volume":"97","author":"D Sulzer","year":"2000","unstructured":"Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karatekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, Zecca L (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A 97:11869\u201311874","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt A","key":"9998_CR78","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neuropharm.2013.08.033","volume":"76","author":"TN Taylor","year":"2014","unstructured":"Taylor TN, Alter SP, Wang M, Goldstein DS, Miller GW (2014) Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology 76(Pt A):97\u2013105","journal-title":"Neuropharmacology"},{"key":"9998_CR79","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.neuropharm.2016.03.034","volume":"107","author":"AM Teema","year":"2016","unstructured":"Teema AM, Zaitone SA, Moustafa YM (2016) Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental parkinsonism: influence on angiogenesis. Neuropharmacology 107:432\u2013450","journal-title":"Neuropharmacology"},{"key":"9998_CR80","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mds.10332","volume":"18","author":"P Teismann","year":"2003","unstructured":"Teismann P, Tieu K, Cohen O, Choi DK, Wu DC, Marks D, Vila M, Jackson-Lewis V, Przedborski S (2003) Pathogenic role of glial cells in Parkinson\u2019s disease. Mov Disord 18:121\u2013129","journal-title":"Mov Disord"},{"key":"9998_CR81","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.pneurobio.2008.05.003","volume":"85","author":"A Toulouse","year":"2008","unstructured":"Toulouse A, Sullivan AM (2008) Progress in Parkinson\u2019s disease\u2014where do we stand? Prog Neurobiol 85:376\u2013392","journal-title":"Prog Neurobiol"},{"key":"9998_CR82","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bbr.2014.11.002","volume":"279","author":"C Wrangel von","year":"2015","unstructured":"von Wrangel C, Schwabe K, John N, Krauss JK, Alam M (2015) The rotenone-induced rat model of Parkinson\u2019s disease: behavioral and electrophysiological findings. Behav Brain Res 279:52\u201361","journal-title":"Behav Brain Res"},{"key":"9998_CR83","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40035-015-0042-0","volume":"4","author":"Q Wang","year":"2015","unstructured":"Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener 4:19","journal-title":"Transl Neurodegener"},{"key":"9998_CR84","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/1573406410666140925151845","volume":"11","author":"B Yulug","year":"2015","unstructured":"Yulug B, Hanoglu L, Kilic E (2015) The neuroprotective role of vesicular monoamine transporter 2 in neurodegenerative diseases. Med Chem 11:104\u2013108","journal-title":"Med Chem"},{"key":"9998_CR85","doi-asserted-by":"publisher","first-page":"774","DOI":"10.4103\/0253-7613.103300","volume":"44","author":"SA Zaitone","year":"2012","unstructured":"Zaitone SA, Abo-Elmatty DM, Elshazly SM (2012a) Piracetam, vinpocetine ameliorate rotenone-induced parkinsonism in rats. Indian J Pharmacol 44:774\u2013779","journal-title":"Indian J Pharmacol"},{"key":"9998_CR86","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.pbb.2011.09.002","volume":"100","author":"SA Zaitone","year":"2012","unstructured":"Zaitone SA, Abo-Elmatty DM, Shaalan AA (2012b) Acetyl-L-carnitine alpha-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson\u2019s disease therapy. Pharmacol Biochem Behav 100:347\u2013360","journal-title":"Pharmacol Biochem Behav"},{"key":"9998_CR87","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S1734-1140(13)71479-8","volume":"65","author":"SA Zaitone","year":"2013","unstructured":"Zaitone SA, Hammad LN, Farag NE (2013) Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice. Pharmacol Rep 65:1213\u20131226","journal-title":"Pharmacol Rep"},{"key":"9998_CR88","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00401-008-0361-7","volume":"116","author":"L Zecca","year":"2008","unstructured":"Zecca L, Wilms H, Geick S, Claasen JH, Brandenburg LO, Holzknecht C, Panizza ML, Zucca FA, Deuschl G, Sievers J, Lucius R (2008) Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson\u2019s disease. Acta Neuropathol 116:47\u201355","journal-title":"Acta Neuropathol"},{"key":"9998_CR89","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12640-009-9140-z","volume":"19","author":"W Zhang","year":"2011","unstructured":"Zhang W, Phillips K, Wielgus AR, Liu J, Albertini A, Zucca FA, Faust R, Qian SY, Miller DS, Chignell CF, Wilson B, Jackson-Lewis V, Przedborski S, Joset D, Loike J, Hong JS, Sulzer D, Zecca L (2011) Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson\u2019s disease. Neurotox Res 19:63\u201372","journal-title":"Neurotox Res"},{"key":"9998_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2741\/E591","volume":"5","author":"W Zhang","year":"2013","unstructured":"Zhang W, Zecca L, Wilson B, Ren HW, Wang YJ, Wang XM, Hong JS (2013) Human neuromelanin: an endogenous microglial activator for dopaminergic neuron death. Front Biosci 5:1\u201311","journal-title":"Front Biosci"},{"key":"9998_CR91","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12640-013-9435-y","volume":"25","author":"FA Zucca","year":"2014","unstructured":"Zucca FA, Basso E, Cupaioli FA, Ferrari E, Sulzer D, Casella L, Zecca L (2014) Neuromelanin of the human substantia nigra: an update. Neurotox Res 25:13\u201323","journal-title":"Neurotox Res"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-019-9998-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12640-019-9998-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-019-9998-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T19:07:38Z","timestamp":1579720058000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12640-019-9998-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["9998"],"URL":"https:\/\/doi.org\/10.1007\/s12640-019-9998-3","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]},"assertion":[{"value":"25 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}